Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Equity Ratio (2016 - 2025)

Sunshine Biopharma's Equity Ratio history spans 14 years, with the latest figure at 0.77 for Q4 2025.

  • For Q4 2025, Equity Ratio changed 0.4% year-over-year to 0.77; the TTM value through Dec 2025 reached 0.77, changed 0.4%, while the annual FY2025 figure was 0.77, 0.4% changed from the prior year.
  • Equity Ratio reached 0.77 in Q4 2025 per SBFM's latest filing, roughly flat from 0.77 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 1.0 in Q2 2022 to a low of 0.58 in Q1 2021.
  • Average Equity Ratio over 5 years is 0.58, with a median of 0.78 recorded in 2023.
  • Peak YoY movement for Equity Ratio: surged 669.7% in 2022, then dropped 27.5% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.1 in 2021, then soared by 669.7% to 0.74 in 2022, then increased by 4.86% to 0.78 in 2023, then decreased by 0.84% to 0.77 in 2024, then decreased by 0.4% to 0.77 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Equity Ratio are 0.77 (Q4 2025), 0.77 (Q3 2025), and 0.8 (Q2 2025).